Glycyl-glutamine-L-valine

Glycyl-Glutamine-L-Valine: A Reference Overview

Preface: Nomenclature and Compositional Identity

The label ingredient "glycyl-glutamine-L-valine" does not correspond to a single, discretely characterized compound registered in major chemical databases, peer-reviewed pharmacological literature, official pharmacopeias, or government dietary supplement monographs (NIH Office of Dietary Supplements, EFSA, EMA). A thorough search of PubMed/NCBI, PubChem, the WHO monograph library, Examine.com, and ESCOP resources returns no studies, safety assessments, or efficacy data for this exact three-component string used as the name of a single tripeptide or blend.

What the scientific and regulatory literature does document extensively are the two principal components implied by the name: glycyl-L-glutamine (Gly-Gln), an endogenous dipeptide derived from β-endorphin and studied as a nutritional and neuropeptide agent; and L-valine, an essential branched-chain amino acid (BCAA). This article therefore covers each documented component in full scientific depth, with an honest statement where the combined entity lacks independent evidence.

---

Part I: Glycyl-L-Glutamine (Gly-Gln)

1. Identity

Chemical name: N-glycyl-L-glutamine. Synonyms: Glycylglutamine; Gly-Gln. Molecular formula: C₇H₁₃N₃O₄; PubChem CID 123913. CAS numbers: Two CAS numbers appear in the literature—CAS 13115-71-4 (anhydrous form) and CAS 172669-64-6 (hydrate form). Molecular weight: The dipeptide glycyl-L-glutamine weighs 203.22 daltons, with glutamine making up approximately 72 percent of the total weight.

Structure and origin: Glycyl-glutamine (Gly-Gln) is an endogenous dipeptide that is synthesized from β-endorphin post-translationally. Specifically, glycyl-glutamine (Gly-Gln; β-endorphin^30–31) is an endogenous dipeptide synthesized from β-endorphin^1–31. In structural terms, it is a C-terminal dipeptide formed by glycine bonded via a peptide bond to L-glutamine. Glycyl-L-glutamine is a C-terminal dipeptide fragment of β-endorphin.

Natural sources: The β-endorphin fragments β-endorphin(1–27) and β-endorphin(1–26) had been isolated from porcine and bovine pituitary prior to the identification of the C-terminal dipeptide glycyl glutamine; Parish and colleagues described its isolation from porcine pituitary and presented evidence for its presence in sheep brain stem. Gly-Gln is synthesized through the posttranslational processing of β-endorphin in brain stem regions that control respiration and autonomic function. It is therefore found endogenously in mammalian nervous tissue, pituitary gland, and, in smaller amounts, in peripheral tissues.

Common preparative forms: For research and nutritional applications, Gly-Gln is produced synthetically. One documented synthetic route involves dissolving glycine methyl ester hydrochloride in L-glutamine ionic liquid and allowing the reaction to proceed to form the dipeptide, confirmed by HPLC. The amino acids L-Gln and Gly-OMe·HCl used are commercially available, and the dipeptide glycyl glutamine (Gly-Gln) can be confirmed by HPLC analysis. Microbial production methods using engineered Escherichia coli strains with selective deletions of peptidase genes have also been documented as biosynthetic manufacturing routes. Commercial reagent-grade preparations are available as the monohydrate at purities of ≥98%. Gly-Gln is also produced by enzymatic or acid hydrolysis of protein sources rich in glutamine.

Pharmaceutical and nutritional forms: Free glutamine is limited in practical application due to its instability in acidic environments and poor absorption efficiency in the small intestine; in contrast, dipeptides of glutamine are more storage stable and soluble, and can be efficiently transported across intestinal epithelial cells via the peptide transporter 1 (PepT1), where they release the active free glutamine. As a nutritional ingredient, Gly-Gln has been studied primarily in powder and solution forms for enteral and parenteral administration.

2. Traditional and Historical Use

Glycyl-L-glutamine has no documented history of use in traditional or folk medicine systems. It is not a constituent of any traditional botanical remedy and is not referenced in historical pharmacopeias or ethnobotanical records. It became known to science only after the characterization of the β-endorphin precursor protein (proopiomelanocortin, or POMC) and the subsequent identification of its post-translational cleavage products. The primary mechanism of activation of intracellular prohormones appears to involve proteolytic cleavage at sequences of consecutive basic residues; all the known biologically active peptides derived from the prohormone of corticotropin and β-endorphin appear to be excised initially by enzymes with this specificity, and the C-terminal peptide β-endorphin(1–31) is generated by cleavage at a lysyl–arginine sequence, with additional cleavage giving rise to β-endorphin(1–27) and β-endorphin(1–26). The C-terminal dipeptide Gly-Gln was not reported scientifically until 1983.

The interest in Gly-Gln as a nutritional supplement ingredient grew separately from its neuropeptide biology: parallel research from the 1990s onward investigated glutamine dipeptides as more bioavailable alternatives to free glutamine in clinical and sports nutrition settings. This nutritional application does not have "traditional" roots but is a modern evidence-based inquiry.

3. Key Constituents and Active Compounds

Gly-Gln is itself the active entity. Upon intestinal absorption and hydrolysis, it yields its two constituent amino acids, glycine and L-glutamine, each of which carries distinct biological activities. Glycine itself has a certain antioxidant potential, which can further relieve oxidative stress by participating in glutathione synthesis. L-glutamine is the primary energy substrate for intestinal epithelial cells and is central to immune cell metabolism.

Glycyl-glutamine, as an enzymatic cleavage product of β-endorphin, is apparently an endogenous antagonist of β-endorphin(1–31) in several systems. It is described as an active and stable glutamine-containing neuropeptide compared to free glutamine.

4. Mechanisms of Action

4.1 Intestinal Peptide Transport and Glutamine Delivery

The structural difference of peptide bonding matters enormously for absorption: the intestinal tract has specialized transport systems for dipeptides and tripeptides that work faster and more efficiently than the systems for single amino acids. When glutamine peptides are consumed, they use these rapid transport mechanisms to cross the intestinal barrier largely intact; once inside the body, enzymes quickly break them down into their component amino acids, releasing glutamine where it can be used.

4.2 Intestinal Barrier and Tight Junction Regulation

Studies have shown that bioactive peptides, especially glutamine peptides, have the ability to regulate tight junctions and improve physical barriers. For Gly-Gln specifically, dietary supplementation with Gly-Gln significantly increased the mRNA expression of ZO-1, Occludin, and Claudin-1 in the jejunum and ileum, suggesting a strengthening of the intestinal epithelial barrier; these improvements may be partially mediated via the amino acid-sensitive mammalian target of rapamycin (mTOR) pathway, which plays a central role in sensing cellular nutrient status and regulating various physiological processes, and in the gut, activation of the mTOR pathway promotes epithelial renewal, enhances tight junction protein expression, and supports immunoglobulin production.

4.3 Gut Microbiota Modulation

Dietary Gly-Gln supplementation beneficially altered the gut microbiota by increasing bacterial loading, elevating alpha diversity, and increasing the relative abundance of anaerobes and fiber-degrading bacteria (Phylum Fibrobacteres); accordingly, the microbial metabolites short-chain fatty acids (SCFAs) in both colon and ileum, as well as the downstream endocrine peptides in the ileum, increased.

4.4 Jejunal Cell Proliferation and Anti-Apoptotic Effects

The glycyl-glutamine dipeptide increased the glutaminase activity, diamine oxidase (DAO) activity, and protein content of jejunal tissues in a concentration-dependent manner; these results indicated that glycyl-glutamine dipeptide affected jejunum development and adaptation of weaned piglets, and the function may be fulfilled by enhancing the glutamine-related enzyme activity, thereby increasing the consumption of glutamine, and then improving jejunal cell proliferation and suppressing cell apoptosis. The effects relied in a dose-dependent manner, and the maximum effect was achieved at 20–30 mmol L⁻¹ glycyl-glutamine dipeptide.

4.5 Neuropeptide and Opioid System Modulation

Glycyl-glutamine and other post-translationally derived β-endorphin peptides display little or no affinity for opioid receptors. Instead, its modulation of the opioid system appears to operate via non-opioid receptor-mediated mechanisms. This concept is supported by reports that Gly-Gln inhibits some pharmacological effects produced by opioids; specifically, it attenuates the hypotension and respiratory depression caused by central β-endorphin^1–31 or morphine administration and inhibits the grooming response produced by β-endorphin^1–31.

One documented mechanism is the inhibition of morphine-induced dopamine efflux. Gly-Gln was shown to prevent acquisition of morphine-conditioned place preference without interfering with morphine analgesia; the hypothesis that Gly-Gln inhibits morphine reward by blocking morphine-induced dopamine efflux in the nucleus accumbens was tested by microdialysis.

4.6 Acetylcholinesterase Regulation

Glycyl-L-glutamine has been shown to maintain the acetylcholinesterase content of the preganglionically denervated superior cervical ganglion of the cat; it acts at a stage prior to the aggregation of the monomeric G1 form of the enzyme to higher polymers, and it has been proposed that it may do so by regulating the transcription of DNA to mRNA, in a manner analogous to that of triiodothyronine. In autonomic ganglia there is evidence that the presynaptic neurone releases a substance (possibly glycyl-L-glutamine) that acts postjunctionally to stimulate the synthesis of acetylcholinesterase.

5. Scientific Evidence by Area of Use

5.1 Gastrointestinal Health — Intestinal Barrier Function

Preclinical (animal) evidence: Glycyl-glutamine was shown to alleviate intestinal barrier damage caused by the weaning of piglets by regulating intestinal flora. A study examining glycyl-glutamine supplementation in LPS-challenged piglets found that dietary GlyGln supplementation improved the LPS-induced inflammation response and damage to the ileum morphology by increasing interleukin-10, tight junction proteins, villus height, and the ratio of villus height to crypt depth, while decreasing the crypt depth. A 2025 study published in Animals (PMC) reported that 0.25%, 0.375%, or 0.50% Gly-Gln supplementation improved growth performance, enhanced serum immunity and antioxidant capacity, and improved the apparent digestibility of nutrients; additionally, it upregulated the mRNA expression of jejunal tight junction proteins ZO-1, Occludin, and Claudin-1; the findings confirm the minimum effective additive dose of Gly-Gln in weaning piglet feed is 0.25%.

Work on rats after liver transplantation showed that Gly-Gln by parenteral supplementation is hydrolyzed to release glutamine, which improves intestinal barrier function in intestinal injury, and most patients after liver transplantation suffer from intestinal barrier dysfunction. A referenced animal surgery study, cited in the SpringerLink chapter on glutamine and GI tight junctions, noted that enteral supplementation with glycyl-glutamine improves intestinal barrier function after liver transplantation in rats. An additional referenced animal study found that glycyl-glutamine-enriched long-term total parenteral nutrition attenuates bacterial translocation following small bowel transplantation in the pig (J Surg Res. 1999;82(1):106–11).

Evidence strength: The intestinal barrier evidence is exclusively preclinical—conducted in piglets, rats, and cats. No human clinical trials on Gly-Gln's effect on intestinal barrier function have been identified in peer-reviewed literature. The mechanistic findings are consistent and biologically plausible but cannot be extrapolated directly to human dosing or outcomes.

5.2 Opioid Dependence, Tolerance, and Withdrawal

Preclinical (animal) evidence: A series of rodent studies published in peer-reviewed pharmacology journals established that Gly-Gln modulates multiple aspects of opioid-related behavior. Gly-Gln is an endogenous dipeptide synthesized from β-endorphin; previous investigations showed that Gly-Gln inhibits the cardiovascular and respiratory depression caused by morphine and β-endorphin(1–31), but it does not interfere with opioid analgesia.

In place preference experiments, rats conditioned with morphine sulfate (2.5 mg/kg i.p.) or saline on alternate days for six days were tested on day seven; glycyl-glutamine (1–100 nmol i.c.v.) pretreatment inhibited acquisition of a conditioned place preference to morphine significantly. Regarding tolerance and dependence, rats were treated with morphine (10 mg/kg i.p.) twice daily for seven days and morphine antinociception was evaluated with the tail-flick test; glycyl-glutamine (100 nmol i.c.v.) pretreatment delayed the onset of morphine tolerance significantly and partially reversed pre-established tolerance.

Regarding respiratory effects, the hypothesis that Gly-Gln administration to conscious rats would prevent the respiratory depression caused by morphine without affecting morphine antinociception was tested; rats were administered Gly-Gln (1–100 nmol) or saline intracerebroventricularly followed, 5 minutes later, by morphine (40 nmol icv), and Gly-Gln pretreatment inhibited morphine-induced hypercapnia, hypoxia, and acidosis significantly.

Evidence strength: All studies are animal (rodent) studies, administered centrally (intracerebroventricularly) at nanomolar doses. There are no human clinical trials evaluating Gly-Gln for opioid dependence or respiratory effects. Central (icv) administration is not a practical route for supplement use. This body of evidence is mechanistically important but entirely preclinical.

5.3 Nicotine Dependence

Preclinical (animal) evidence: A 2006 study in European Journal of Pharmacology found that rats were conditioned with nicotine (0.6 mg/kg, s.c.) for four days and tested on day five; glycyl-glutamine (100 nmol i.c.v.) inhibited acquisition and expression of a nicotine place preference significantly. Furthermore, glycyl-glutamine blocked acquisition of place aversion to mecamylamine but not U50,488, a kappa opioid receptor agonist; glycyl-glutamine thus inhibits the rewarding effects of nicotine and attenuates withdrawal in nicotine-dependent rats.

Evidence strength: Animal only. No human studies exist. As with the opioid studies, the dose route (intracerebroventricular injection) is not applicable to supplement administration.

5.4 Neurochemistry — Acetylcholinesterase Synthesis

Preclinical (in vitro and animal) evidence: A body of work by George B. Koelle and colleagues, published in the Proceedings of the National Academy of Sciences USA and Trends in Pharmacological Sciences, documented that Gly-Gln increases the A12 and G4 forms of acetylcholinesterase in cultured embryonic rat skeletal muscle, and since Gly-Gln meets the criteria established for the neurotrophic factor in extracts of central nervous system/sciatic nerves that maintains AcChoEase and butyrylcholinesterase in the denervated cat superior cervical ganglion, it was tested and shown to maintain these enzymes in vivo. A study from PMC found that glycyl-L-glutamine was found to affect the rate of regeneration of acetylcholinesterase in the rat gastrocnemius muscle after diisopropyl phosphorofluoridate administration, published in Proc Natl Acad Sci USA (1989;86(11):4331–4333).

Evidence strength: In vitro and animal only. These findings identify a potential neurotrophic/transcriptional regulatory role for Gly-Gln in cholinergic neuroscience but have not been translated to human clinical studies.

5.5 Immune Modulation and Antioxidant Capacity

Preclinical evidence: A study investigating the effects of glycyl-glutamine supplementation on weaned piglets showed that 0.25%, 0.375%, or 0.50% Gly-Gln supplementation improved growth performance, enhanced serum immunity and antioxidant capacity, and improved the apparent digestibility of nutrients. Additionally, a study on LPS-challenged animals found that multiple studies have shown that glutamine peptides can alleviate the damage of biological barriers by regulating the community diversity, evenness, richness, and composition of intestinal flora.

Evidence strength: Animal (piglet) studies only. No human clinical trials on immunological or antioxidant outcomes of Gly-Gln supplementation have been identified.

6. Dosage Forms and Reported Doses

Reported dosages in the scientific literature vary considerably by application and route:

• Animal dietary supplementation studies (piglets): Gly-Gln was studied at 0%, 0.125%, 0.25%, 0.375%, and 0.50% of feed weight; dietary supplementation with 0.25%, 0.375%, or 0.50% Gly-Gln significantly increased average daily gain, average daily feed intake, and final weight.
• In vitro jejunal tissue studies: The effects were concentration-dependent, with the maximum effect achieved at 20–30 mmol L⁻¹; the study tested concentrations of 2, 4, 10, 20, and 30 mmol L⁻¹.
• Rodent neurological studies (icv route): Glycyl-glutamine at 1–100 nmol i.c.v. pretreatment was used to inhibit acquisition of morphine conditioned place preference. At 100 nmol i.c.v., pretreatment significantly delayed the onset of morphine tolerance.
• Respiratory depression studies (rodents, icv): Rats were administered Gly-Gln at 1–100 nmol intracerebroventricularly.

No human clinical dosing has been established for glycyl-L-glutamine in any published study. Extrapolation of animal dietary percentages or nanomolar icv doses to human oral supplementation is not supported by current evidence.

7. Safety Considerations

No dedicated human safety or toxicology studies for glycyl-L-glutamine as a dietary supplement have been identified in peer-reviewed literature, government databases, or official monographs. At present, most researchers still use synthetic glutamine dipeptides as the research object to study their physiological function in the human or animal body, while the synthetic method has the disadvantages of high cost, complicated process, environmental pollution, and so on.

Since Gly-Gln is an endogenous human neuropeptide naturally present in pituitary and brain stem tissue, it is generally regarded as having a low inherent toxicity at physiological levels; however, this does not establish a safety profile for supplemental doses. No formal NOAEL (No Observed Adverse Effect Level), LD50, or human toxicity data for oral Gly-Gln supplementation have been published in the sources identified. No drug interaction studies are available in the public literature.

---

Part II: L-Valine

1. Identity

Branched-chain amino acids (BCAAs), namely L-isoleucine, L-leucine, and L-valine, are essential amino acids that cannot be synthesized in higher organisms and are important nutrition for humans as well as livestock. L-valine is a small, hydrophobic, branched-chain amino acid with the molecular formula C₅H₁₁NO₂. It is one of the three BCAAs alongside L-leucine and L-isoleucine.

Natural sources: L-valine is found in virtually all protein-containing foods. Whey protein is particularly rich in the branched-chain amino acids L-leucine, L-isoleucine, and L-valine. Other rich dietary sources include meat, fish, dairy products, eggs, legumes, and soy protein. The BCAAs are nutritionally essential in that they cannot be synthesized endogenously by humans and must be supplied by diet; they differ from other essential amino acids in that the liver lacks the enzymes necessary for their catabolism.

Common forms: L-valine is commercially available as a free-form crystalline powder for supplementation, as a component of BCAA blends (typically in a 2:1:1 ratio of leucine:isoleucine:valine), and as a constituent of protein hydrolysates. BCAAs are also valued as synthetic intermediates for pharmaceuticals.

2. Traditional and Historical Use

L-valine, as an isolated amino acid supplement, has no documented history of use in traditional or folk medicine. Its essentiality in human nutrition has been known since the mid-20th century following systematic research on amino acid requirements. Clinical interest in isolated BCAA supplementation, including valine, began in the 1970s–1980s in the context of hepatic encephalopathy, muscle wasting diseases, and sports nutrition. These are modern medical and nutritional applications, not traditional ethnomedical practices.

3. Key Constituents and Established Mechanisms of Action

In addition to their function as structural components of proteins, BCAAs also appear to exert regulatory control of protein metabolism; in rodent tissue in vitro, increased concentrations of BCAAs stimulate protein synthesis and inhibit protein catabolism, whereas other amino acid mixtures lacking BCAAs have no such influence.

L-valine has a distinct mechanism within the central nervous system. The branched-chain amino acid L-valine competes with tryptophan for transport into the brain and has previously been shown to decrease brain 5-HT synthesis. Additionally, differential roles of BCAAs in lipid metabolism have been illustrated, with preliminary evidence that exclusively valine contributes to the endogenous formation of odd-chain fatty acids (OCFA), which is important for understanding these metabolites in metabolic health.

4. Scientific Evidence by Area of Use

4.1 Exercise Performance and Muscle Recovery

Human and animal evidence (BCAA context): L-valine is almost always studied as part of BCAA mixtures rather than in isolation. Isoleucine, leucine, and valine, also called BCAAs, are portrayed as a potential ergogenic supplement; a systematic review of the existing evidence on BCAA supplementation on physical exercise searched PubMed, Scopus, Cochrane Library and SciELO from 2000 to May 2020; twelve randomized controlled trials were selected, most including physically active individuals or untrained males, with an intervention period ranging from 1 day to 8 weeks and a mean BCAA dose of 19.5 g/day. The evidence for valine specifically is not separable from these combination studies.

4.2 Serotonin Hypothesis of Fatigue (Animal Evidence)

Animal evidence: An animal study evidenced that acute intensive exercise stimulates 5-HT metabolism in the rat hippocampus, and that pre-exercise administration of L-valine prevents, via a limiting effect on 5-HT synthesis, exercise-induced 5-HT release; pre-exercise administration of L-valine significantly prevents the exercise-induced 5-HT release, maintaining 5-HT levels at baseline during exercise and recovery. This finding is consistent with the established transport competition at the blood-brain barrier, but human evidence directly attributing fatigue reduction to L-valine alone is not established in the identified sources.

4.3 Appetite Regulation and Energy Intake

Human evidence (negative finding): A clinical study investigated the effects of L-valine specifically on gastrointestinal function. Whether L-valine affects energy intake, and the gastrointestinal functions involved in the regulation of energy intake, as well as blood glucose, in humans was unknown; investigators studied the effects of intraduodenally administered L-valine on antropyloroduodenal pressures, plasma cholecystokinin, blood glucose and energy intake. Both L-leucine and L-isoleucine have been shown to modulate gut motor and hormone functions, energy intake and/or blood glucose; however, there is very little information about the effects of L-valine.

4.4 Neurological Recovery (BCAA Context)

Small human trials: Two small, randomized, placebo-controlled trials have been published reporting that BCAA supplementation enhanced cognitive recovery by patients with TBI (Aquilani et al., 2005, 2008); however, these studies began administering BCAAs anywhere from 19 to 140 days after injury. These trials used combined BCAA preparations and the specific contribution of L-valine cannot be separated.

4.5 Valine Requirements in Humans

Human metabolic study: Six young adult men received four L-amino acid-based diets for five days supplying either 20 or 10 mg valine per kg body weight per day, each in combination with 80 or 40 mg leucine per kg body weight per day; on day six they were studied with an 8-hour continuous intravenous infusion of [1-¹³C]valine to determine valine oxidation; valine oxidation in the fasted state was similar among all diets but was lower in the fed state for the 10 vs. 20 mg valine per kg intake. These findings support a mean valine requirement estimate of approximately 20 mg·kg⁻¹·d⁻¹.

5. Dosage Forms and Reported Doses

• Dietary requirement estimate (human metabolic study): Approximately 20 mg·kg⁻¹·d⁻¹ as a mean valine requirement estimate.
• BCAA supplementation trials (combined): The mean BCAA dose used in physical exercise RCTs was 19.5 g/day, across intervention periods ranging from 1 day to 8 weeks.
• ALS trial (combined BCAA, valine dose isolated): In a referenced double-blind randomized trial in 22 ALS patients, the regimen included daily 12 grams of L-leucine, 8 grams of L-isoleucine, and 6.4 grams of L-valine, given orally.

---

Part III: The Combination "Glycyl-Glutamine-L-Valine" — Assessment of the Combined Entity

As established at the outset, "glycyl-glutamine-L-valine" as a single named tripeptide (i.e., a molecule with the amino acid sequence Gly-Gln-Val linked by peptide bonds) does not appear in any peer-reviewed study, government database, pharmacopeia, or authoritative evidence database identified through systematic searching of PubMed/NCBI, PubChem, WHO, NIH ODS, EFSA, ESCOP, or Examine.com. No CAS number, molecular weight, structural data, clinical study, or safety record is available for this putative tripeptide as a distinct compound.

If the label name refers instead to a blend — that is, the co-administration of the glycyl-L-glutamine dipeptide together with free L-valine — no human clinical studies investigating this specific combination have been found. The biological plausibility of a blend would rest on the independent evidence profiles of Gly-Gln (principally preclinical intestinal barrier and neuropeptide research) and L-valine (principally BCAA metabolism and essential amino acid roles). However, synergistic, additive, or antagonistic interactions between Gly-Gln and L-valine as a formulated combination are not documented in any identified peer-reviewed source.

Glutamine peptides have been found to be a stable substitute for glutamine monomer, and they are increasingly studied in nutrition and physiology due to their functional properties. This general trend in research does not, however, constitute evidence for any specific combination product.

---

Summary of Evidence Strength

• Glycyl-L-glutamine — intestinal barrier/GI health: Consistent preclinical (animal) evidence; no human clinical trials identified.
• Glycyl-L-glutamine — opioid/nicotine system modulation: Rodent preclinical evidence only; route of administration (intracerebroventricular) not applicable to oral supplementation.
• Glycyl-L-glutamine — cholinergic/acetylcholinesterase effects: In vitro and cat/rat models only; no human translation.
• L-valine — BCAA-related muscle/performance outcomes: Human RCT evidence exists but for combined BCAA mixtures, not isolated valine; valine-specific evidence is limited.
• L-valine — serotonergic/fatigue mechanisms: Animal studies only.
• "Glycyl-glutamine-L-valine" as a combination or single tripeptide: No peer-reviewed evidence identified.

References

• Parish DC, Smyth DG, Normanton JR, Wolstencroft JH. "Glycyl glutamine, an inhibitory neuropeptide derived from beta-endorphin." Nature. 1983;306:267–270. PubMed PMID: 6316148.
• Cavun S, Göktalay G, Millington WR. "Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal." J Pharmacol Exp Ther. 2005;315(2):949–958. PubMed PMID: 16079299.
• Göktalay G, Cavun S, Levendusky MC, Hamilton JR, Millington WR. "Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal." Eur J Pharmacol. 2006;530(1–2):95–102. PubMed PMID: 16364288.
• Owen MD, Unal CB, Callahan MF, et al. "Glycyl-glutamine inhibits the respiratory depression, but not the antinociception, produced by morphine." Am J Physiol. 2000;279:R1944–R1948. PubMed PMID: 11049880.
• Basaran NF, Buyukuysal RL, Millington WR, Cavun S. "Glycyl-glutamine (β-endorphin30-31) inhibits morphine-induced dopamine efflux in the nucleus accumbens." Naunyn-Schmiedeberg's Arch Pharmacol. 2010;381(5):467–475.
• Cavun S et al. "Glycyl-Glutamine, an Endogenous β-Endorphin-Derived Peptide, Inhibits Morphine-Induced Conditioned Place Preference, Tolerance, Dependence, and Withdrawal." J Pharmacol Exp Ther. 2025 (ScienceDirect).
• Koelle GB, Sanville UJ, Wall SJ. "Glycyl-L-glutamine, a precursor, and glycyl-L-glutamic acid, a neurotrophic factor for maintenance of acetylcholinesterase and butyrylcholinesterase in the preganglionically denervated superior cervical ganglion of the cat in vivo." Proc Natl Acad Sci USA. 1985;82(15):5213–5217. PubMed PMID: 3860856.
• Koelle GB et al. "Glycyl-L-glutamine opposes the fall in choline acetyltransferase in the denervated superior cervical ganglion of the cat." PMC298665.
• Koelle GB. "Enhancement of acetylcholinesterase synthesis by glycyl-L-glutamine: an example of a small peptide that regulates differential transcription?" Trends Pharmacol Sci. 1988;9(9):318–321.
• Jiang X et al. "Dietary Glycyl-Glutamine Supplementation Improves Growth, Immunity, Antioxidant Capacity, and Apparent Digestibility of Weaned Piglets." Animals. 2025. PMC12427411.
• Yan H et al. "Modulation of Gut Microbial Community and Metabolism by Dietary Glycyl-Glutamine Supplementation May Favor Weaning Transition in Piglets." Front. Microbiol. 2020;10:3125. PMC7025575.
• "Dietary glycyl-glutamine supplementation ameliorates intestinal integrity, inflammatory response, and oxidative status in association with the gut microbiota in LPS-challenged piglets." Food & Function. RSC Publishing. 2021.
• "Enteral supplementation with glycyl-glutamine improves intestinal barrier function after liver transplantation in rats." PubMed PMID: 21813386.
• Wang H et al. "The Effect of Glycyl-Glutamine Dipeptide Concentration on Enzyme Activity, Cell Proliferation and Apoptosis of Jejunal Tissues from Weaned Piglets." ScienceDirect. 2011.
• "Glutamine Peptides: Preparation, Analysis, Applications, and Their Role in Intestinal Barrier Protection." Nutrients. 2025;17(6):1017. MDPI.
• PubChem. "Glycyl-L-glutamine." CID 123913. National Center for Biotechnology Information.
• Chaouloff F et al. "Evidence that the branched-chain amino acid L-valine prevents exercise-induced release of 5-HT in rat hippocampus." Brain Res. 2001;908(2):208–212. PubMed PMID: 11510866.
• "The branched-chain amino acids valine and leucine have differential effects on hepatic lipid metabolism." PubMed PMID: 32506644.
• "Intraduodenal Administration of L-Valine Has No Effect on Antropyloroduodenal Pressures, Plasma Cholecystokinin Concentrations or Energy Intake in Healthy, Lean Men." PMC6356499.
• Young VR et al. "Branched-chain amino acid interactions with reference to amino acid requirements in adult men: valine metabolism at different leucine intakes." Am J Clin Nutr. 1991. PubMed PMID: 1858703.
• "Branched-Chain Amino Acids." PubMed PMID: 27872960.
• Institute of Medicine. "Branched-Chain Amino Acids." In: Nutrition and Traumatic Brain Injury. NCBI Bookshelf NBK209312.
• "The effect of branched-chain amino acids supplementation in physical exercise: A systematic review of human randomized controlled trials." ScienceDirect. 2022.